المؤلفون: Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Beksac M; Department of Hematology, Ankara University School of Medicine, Ankara, Turkey., van der Holt B; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Aquino S; IRCCS Azienda Ospedaliera Universitaria San Martino, IST Instituto Nazionale per la Ricerca sul Cancro, Genova, Italy., Ludwig H; Wilhelminen Cancer Research Institute, c/o Wilhelminenspital, Vienna, Austria., Zweegman S; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Zander T; Medical Oncology, Luzerner Kantonshospital, Luzern, Switzerland., Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy., Wester R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Hajek R; University Hospital Ostrava, Ostrava, Czech Republic., Pantani L; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy., Dozza L; Department of Experimental, Diagnostic and Experimental Medicine, Seràgnoli Institute of Hematology, Bologna University School of Medicine, S. Orsola Malpighi Hospital, Bologna, Italy., Gay F; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Cafro A; ASST Grande Ospedale Metropolitano, Niguarda, Milan, Italy., De Rosa L; Ospedale San Camillo Forlanini, Rome, Italy., Morelli A; Department of Hematology, Transfusion Medicine and Biotechnology Santo Spirito, Civic Hospital, Pescara, Italy., Gregersen H; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Gulbrandsen N; Department of Hematology, Oslo University Hospital, Oslo, Norway., Cornelisse P; HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Troia R; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Oliva S; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., van de Velden V; Department of Immunology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Wu K; Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium., Ypma PF; Department of Hematology, Haga Ziekenhuis, The Hague, the Netherlands., Bos G; Maastricht University Medical Center, Maastricht, the Netherlands., Levin MD; Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands., Pour L; University Hospital Brno, Brno, Czech Republic., Driessen C; Department of Oncology/Hematology, Kantonsspital, St Gallen, Switzerland., Broijl A; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Croockewit A; Department of Hematology, Radboud University Medical Centre, Nijmegen, the Netherlands., Minnema MC; Department of Hematology, University Medical Centre Utrecht, the Netherlands., Waage A; Department of Hematology, St Olav Hospital, Trondheim, Norway., Hveding C; Sahlgrenska University Hospital, Gothenburg, Sweden., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Offidani M; Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy., Palumbo GA; Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia,' University of Catania, Catania, Italy., Spencer A; Department of Haematology, Alfred Hospital-Monash University, Melbourne, Australia., Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Cavo M; IRCCS S.Orsola-Malpighi, Istituto di Ematologia 'Seràgnoli,' Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi di Bologna, Bologna, Italy.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 10; Vol. 39 (32), pp. 3613-3622. Date of Electronic Publication: 2021 Sep 14.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Bortezomib/*administration & dosage , Dexamethasone/*administration & dosage , Lenalidomide/*administration & dosage , Multiple Myeloma/*drug therapy, Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/adverse effects ; Consolidation Chemotherapy ; Dexamethasone/adverse effects ; Europe ; Humans ; Lenalidomide/adverse effects ; Maintenance Chemotherapy ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Staging ; Neoplasm, Residual ; Progression-Free Survival ; Time Factors ; Young Adult

المؤلفون: Hengeveld M; Radboud University Nijmegen Medical Center, The Netherlands. M.Hengeveld@crcn.umcn.nl, Suciu S, Karrasch M, Specchia G, Marie JP, Muus P, Petti MC, Rotoli B, Amadori S, Fioritoni G, Leoni P, Morra E, Thaler J, Resegotti L, Fazi P, Vignetti M, Mandelli F, Zittoun R, de Witte T

المصدر: Annals of hematology [Ann Hematol] 2012 Jun; Vol. 91 (6), pp. 825-35. Date of Electronic Publication: 2012 Mar 31.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Consolidation Chemotherapy/*methods , Leukemia, Myeloid, Acute/*drug therapy , Maintenance Chemotherapy/*methods, Adolescent ; Adult ; Age Factors ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Consolidation Chemotherapy/standards ; Europe ; Female ; Hematology/methods ; Hematology/organization & administration ; Humans ; Induction Chemotherapy/methods ; International Cooperation ; Italy ; Maintenance Chemotherapy/standards ; Male ; Medical Oncology/methods ; Medical Oncology/organization & administration ; Middle Aged ; Societies, Medical/organization & administration ; Treatment Outcome ; Young Adult

المؤلفون: Boddu PC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alfayez M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Naqvi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Cancer [Cancer] 2019 Apr 01; Vol. 125 (7), pp. 1091-1100. Date of Electronic Publication: 2018 Dec 06.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Validation Study

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy, Adolescent ; Adult ; Consolidation Chemotherapy ; Cytarabine/administration & dosage ; Europe ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Idarubicin/administration & dosage ; Induction Chemotherapy ; L-Lactate Dehydrogenase/metabolism ; Leukemia, Myeloid, Acute/genetics ; Leukocyte Count ; Male ; Middle Aged ; Mutation ; Nuclear Proteins/genetics ; Nucleophosmin ; Platelet Count ; Prognosis ; Reproducibility of Results ; Retrospective Studies ; Risk Assessment ; Survival Rate ; Young Adult ; fms-Like Tyrosine Kinase 3/genetics

المؤلفون: Willemze R; Roelof Willemze, Constantijn J.M. Halkes, and Erik W.A. Marijt, Leiden University Medical Center, Leiden; Petra Muus, Joop Jansen, and Theo de Witte, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; Stefan Suciu and Liv Meert, European Organisation for Research and Treatment of Cancer Headquarters; Dominique Bron, Hôpital Universitaire, Bordet-Erasme, Brussels; Dominik L.D. Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge; Zwi Berneman, Universitair Ziekenhuis, Antwerpen; Georges Fillet, Centre Hospitalier Universitaire du Sart-Tilman, Liège; Anne Hagemeijer, Center for Human Genetics, University of Leuven, Leuven, Belgium; Giovanna Meloni, Marco Mancini, Silvia Maria Trisolini, and Franco Mandelli, 'Sapienza' University; Sergio Amadori and Adriano Venditti, Tor Vergata University Hospital; Simona Sica, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli; Paola Fazi and Marco Vignetti, Gruppo Italiano Malattie Ematologiche dell' Adulto Foundation, Central Office, Rome; Giorgina Specchia, Università degli Studi di Bari, Bari; Francesco Fabbiano, Ospedali Riuniti 'Villa Sofia-Cervello'; Maria Enza Mitra, Policlinico 'Paolo Giaccone,' Palermo; Francesco Nobile, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria; Marco Sborgia, Azienda Unitá Sanitaria Locale di Pescara, Pescara; Andrea Camera, L'A.O. Universitaria-Università degli Studi di Napoli 'Federico II,' Napoli; Domenico Magro, A.O. Pugliese Ciaccio, Catanzaro; Nicola Cantore, A.O. San Giuseppe Moscati, Avellino; Lorella Melillo, Istituto Di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo; Pietro Leoni, A.O. Nuovo Ospedale Torrette, Ancona; Mario Luppi, A.O. Universitaria di Modena, Modena; Daniela Cilloni, University of Torino, Torino, Italy; Boris Labar, University Hospital Center-Rebro, Zagreb, Croatia; Jean-Pierre Marie, Saint-Antoine Hospital, Assistance Publique-Hopitaux de Paris and University Paris 6; Francois Lef, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Jan 20; Vol. 32 (3), pp. 219-28. Date of Electronic Publication: 2013 Dec 02.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antimetabolites, Antineoplastic/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Cytarabine/*administration & dosage , Induction Chemotherapy/*methods , Leukemia, Myeloid, Acute/*drug therapy, Adolescent ; Adult ; Consolidation Chemotherapy ; Daunorubicin/administration & dosage ; Drug Administration Schedule ; Etoposide/administration & dosage ; Europe ; Female ; Humans ; Infusions, Intravenous ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Mutation ; Risk Assessment ; Risk Factors ; Treatment Outcome